I’m SHOCKED ⚡️⚡️⚡️ Just finished my last presentation of my pharmacy student career. (Also, I might be #TeamLidocaine) #TwitteRx

This week I graduate from UNC Pharmacy where I spent 4 of the most transformative years learning & growing alongside these 6 pharmacy superstars & friends. I’m excited to embark on my next steps as an incoming Johns Hopkins Medicine resident. Here we come #TwitteRx! 👨🏻‍🎓🤩 #Classof2023

As I begin residency tomorrow, this was nice to set the stage and provide perspective on how to progress through this stage of training!

2018 - Interning in Dr.McCurdy’s med chem lab at UF Pharmacy. Deciding between PharmD & PhD. Though I chose PharmD, the culture in his lab was so welcoming that I came back in 2019 and interned again. 2023 - reunited at AACP Meeting. Full circle moment #PharmEd23

Yesterday at #PharmEd23, Paula Paseiro presented a poster on test-optional admission policies and Isabel Cheng, Amanda Savage and the PharmAlliance team led a special podium presentation on their vaccine champion curriculum! AACP

What do we do with SGLT2i when the eGFR goes south of 25❓ 🚨 keep it going ‼️ Subgroup analysis of DAPA-HF & DELIVER with eGFR < 25 showed that dapagliflozin 👉🏼 ⬇️ rates of CV outcomes 👉🏼 safe ✅ when compared w placebo #ESCCongress #CardioTwitter #MedTwitter 🔗

Happy Women Pharmacists Day to all of my incredible women pharmacist colleagues! #WomenPharmacistDay ASHP

If you are interested in ID, working with a great team, and having fun in Nashville, consider attending one of our open house sessions! As an alumni of this program, I have nothing but good things to say!

#Axatilimab is a humanized monoclonal antibody that inhibits CSF-1R signaling and restrains macrophage development Colony-stimulating factor 1 receptor–dependent macrophages are important for cGVHD development and worsening #ASH23

I am so grateful for #PharmGradWishlist making my transition from pharmacy student to pharmacist easier! Thank you for any and all support! #TwitteRx #PharmGradWishlist amazon.com/hz/wishlist/ls…

I moved to this country pursuing my dream of becoming a pharmacist. Last week, I graduated from UNC with Honors and Distinction. My journey has not been easy but I'm grateful for everyone who's helped me along the way! Consider supporting me one last time through #PharmGradWishlist.

‼️Today is #WorldLungCancerDay. It’s an “ERA OF #HOPE” for #Patients with #LungCancer. We celebrate the great progress, but we still have a long way to go. We will keep advancing #CancerResearch & #CancerCare. We will keep the fight FOR and WITH our fearless patients. #LCSM

A new study published in Nature Medicine found that vedolizumab reduces lower-GI #aGvHD 📝 More news: gvhdhub.com #GvHD #MedNews #MedEd

Tarlatamab with anti-PD-L1 as 1L maintenance in ES-SCLC (DeLLphi-303) No DLTs, no fatal TRAEs 9-month OS: 89%!! Impressive results. #WCLC24

An excellent explanation of the differences in mechanism between TCR and CAR-T.

WOW- practice changing MCL trial showing no benefit of autoHCT in uMRD MCL in first remission. Bravo ECOG team. Tim Fenske #ASH24

BREAKING: The FDA's ODAC has voted 8 to 1 against the applicability of the STARGLO trial findings for US patients with relapsed/refractory #DLBCL. This decision impacts the use of glofitamab (Columvi) with GemOx. #lymsm hubs.li/Q03nmsc90

🧵 EHA 2025 Clinical Practice Guidelines for Large B-Cell Lymphoma (LBCL) 1️⃣ Diagnosis & Baseline 🧬 🔹 Biopsy (excisional preferred) 🔹 PET-CT for staging 🔹 IPI & CNS-IPI mandatory 🔹 Molecular: MYC, BCL2/BCL6 (DH/TH) ➡️ poor prognosis 🔹 Baseline MRI/CSF if CNS risk #LBCL

🚫💉 End of chemo in mantle is here ? ENRICH trial (Lancet 2025) 👥 397 untreated MCL (≥60 yrs) 💊 Ibrutinib + Rituximab (IR) vs 💉Immunochemotherapy (R-CHOP / R-Benda) 📊 Primary endpoint: PFS • IR > Chemo — HR 0.69 (0.52–0.90), p = 0.0034 • 🔹 vs R-CHOP HR 0.37

Cytopenias following CAR-T are often prolonged and challenging to manage. Whether growth factor support offers benefit or causes harm in this setting remains a question. G-CSF may or may not help here, it doesn’t seem to harm patients in our cohort. sciencedirect.com/science/articl…